Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients
NCT ID: NCT00658359
Last Updated: 2018-02-23
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
178 participants
INTERVENTIONAL
2008-08-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients
NCT00555789
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
NCT00895583
Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients
NCT00820911
Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidney Transplant Patient
NCT00263328
Renal Function Evaluation After Reduction of Cyclosporine A Dose in Renal Transplant Patients
NCT00213590
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment Arm 1
Treatment Arm 1 will also receive standard of care medications
Cyclosporine
Standard of care
Treatment Arm 2
Treatment Arm 2 will also receive standard of care medications
CP-690,550
CP-690,550 tablets dosed BID Months 12-72
Treatment Arm 3
Treatment Arm 3 will also receive standard of care medications
CP-690,550
CP-690,550 tablets dosed BID Months 12-72
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyclosporine
Standard of care
CP-690,550
CP-690,550 tablets dosed BID Months 12-72
CP-690,550
CP-690,550 tablets dosed BID Months 12-72
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cedars-Sinai Medical Center
Los Angeles, California, United States
Cedars-Sinai MedicalCenter
Los Angeles, California, United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
UCLA Medical Center
Los Angeles, California, United States
Stanford School of Medicine
Palo Alto, California, United States
Stanford University Medical Center
Palo Alto, California, United States
Balboa Institute of Transplantation
San Diego, California, United States
California Institute of Renal Research
San Diego, California, United States
Sharp Memorial Hospital
San Diego, California, United States
California Pacific Medical Center - Pacific Campus
San Francisco, California, United States
California Pacific Medical Center
San Francisco, California, United States
UCSF Medical Center - Long Hospital
San Francisco, California, United States
USCF Medical Center - Connie Frank Transplant Center
San Francisco, California, United States
University of Colorado Denver
Aurora, Colorado, United States
Yale-New Haven Hospital
New Haven, Connecticut, United States
Yale Physicians Building
New Haven, Connecticut, United States
University Of Florida
Gainesville, Florida, United States
Tampa General Hospital
Tampa, Florida, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
NUCATS's Clinical Research Unit
Chicago, Illinois, United States
University of Michigan Health System
Ann Arbor, Michigan, United States
Henry Ford Hospital
Detroit, Michigan, United States
Hurley Medical Center
Flint, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
Investigational Drug Services (IDS) / UNC Healthcare
Chapel Hill, North Carolina, United States
Transplant Clinic/UNC Heathcare
Chapel Hill, North Carolina, United States
UNC Department of Surgery, Clinical Trials Consortium
Chapel Hill, North Carolina, United States
UNC Department of Surgery/Abdominal Transplant Division
Chapel Hill, North Carolina, United States
Division of Pharmacotherapy, School of Pharmacy, University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
University of North Carolina, Department of Medicine/Nephrology
Chapel Hill, North Carolina, United States
Drexel University College of Medicine - Hahnemann University Hospital
Philadelphia, Pennsylvania, United States
Hahnemann University Hospital
Philadelphia, Pennsylvania, United States
Medical University of South Carolina, Department of Transplantation Surgery
Charleston, South Carolina, United States
Nephrology Clinic
Charleston, South Carolina, United States
Dallas Transplant Institute
Dallas, Texas, United States
Annette C. and Harold C. Simmons Transplant Institute at Baylor University Medical Center
Dallas, Texas, United States
Baylor University Medical Center
Dallas, Texas, United States
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Westmead Hospital, Department of Renal Medicine
Westmead, New South Wales, Australia
Central Northern Adelaide Renal and Transplantation Service
Adelaide, South Australia, Australia
The Queen Elizabeth Hospital
Woodville, South Australia, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Hopital Erasme
Anderlecht, Brussels Capital, Belgium
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, , Belgium
Irmandade Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital do Rim e Hipertensao
São Paulo, São Paulo, Brazil
Ambulatorio Pos Transplante do Hospital do Rim a Hipertensao
São Paulo, São Paulo, Brazil
Hospital do Rim e Hipertensao
São Paulo, , Brazil
University of Alberta Hospital
Edmonton, Alberta, Canada
Institut Klinicke a Experimentalni Mediciny
Praha 4 Krc, , Czechia
Hopital Necker
Paris, , France
CHRU de Nancy-Brabois - Service de Nephrologie
Vandœuvre-lès-Nancy, , France
Charite - Universitatsmedizin Berlin
Berlin, , Germany
Istituto di Clinica Chirurgica, Universita Cattolica del Sacro Cuore
Roma, RM, Italy
Azienda Ospedaliero Universitaria di Bologna Policlinico Sant'Orsola Malpighi
Bologna, , Italy
Erasmus Medisch Centrum
Rotterdam, , Netherlands
Oslo universitetssykehus HF- Rikshospitalet
Oslo, , Norway
Akademicki Szpital Kliniczny im. J. Mikulicza - Radeckiego we Wroclawiu
Wroclaw, , Poland
Hospitais da Universidade de Coimbra, EPE
Coimbra, , Portugal
Hospital Curry Cabral
Lisbon, , Portugal
Seoul National University Hospital
Seoul, , South Korea
Department of Surgery, Yonsei University College of Medicine Severance Hospital
Seoul, , South Korea
Asan Medical Center, Department of Surgery
Seoul, , South Korea
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Clinic i Provincial de Barcelona
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-002345-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A3921050
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.